{"id":"epirubicin-cyclophosphamide-docetaxel-bevacizumab","safety":{"commonSideEffects":[{"rate":"40-60%","effect":"Neutropenia"},{"rate":"30-50%","effect":"Anemia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Constipation"},{"rate":"5-20%","effect":"Mucositis"},{"rate":"5-20%","effect":"Hair loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Epirubicin's mechanism of action involves intercalating DNA strands, which inhibits topoisomerase II and induces apoptosis. Cyclophosphamide works by cross-linking DNA, causing cell death. Docetaxel stabilizes microtubules, preventing cell division. Bevacizumab inhibits VEGF, reducing angiogenesis. This combination of drugs targets cancer cells and their blood supply, making it difficult for tumors to grow and spread.","oneSentence":"Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Docetaxel is a taxane that stabilizes microtubules, preventing cell division. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), reducing angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:10.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Locally advanced or metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT00773695","phase":"PHASE2","title":"A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-07","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT00464646","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2007-05","conditions":"Breast Cancer","enrollment":105},{"nctId":"NCT00625898","phase":"PHASE3","title":"BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2008-04","conditions":"Breast Cancer","enrollment":3509},{"nctId":"NCT00820547","phase":"PHASE2","title":"Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2009-01","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT01690325","phase":"PHASE2","title":"Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)","status":"TERMINATED","sponsor":"West German Study Group","startDate":"2012-09","conditions":"Breast Cancer","enrollment":21},{"nctId":"NCT01190345","phase":"PHASE2","title":"Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2010-05","conditions":"Breast Cancer","enrollment":75},{"nctId":"NCT00567554","phase":"PHASE3","title":"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2007-10","conditions":"Breast Cancer","enrollment":2600},{"nctId":"NCT01985841","phase":"PHASE2","title":"Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer","status":"TERMINATED","sponsor":"Hellenic Oncology Research Group","startDate":"2011-10","conditions":"Breast Cancer","enrollment":34},{"nctId":"NCT00262067","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)","status":"UNKNOWN","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Metastatic Breast Cancer","enrollment":1237},{"nctId":"NCT01880385","phase":"PHASE1","title":"Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer","status":"UNKNOWN","sponsor":"Association Tunisienne de lutte Contre le Cancer","startDate":"2011-03","conditions":"Inflammatory Breast Cancer","enrollment":30},{"nctId":"NCT01641406","phase":"PHASE2","title":"\"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer\"","status":"UNKNOWN","sponsor":"Auxilio Mutuo Cancer Center","startDate":"2011-03","conditions":"Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma, Inflammatory Breast Carcinoma","enrollment":60},{"nctId":"NCT00830544","phase":"PHASE2","title":"Study of Neoadjuvant Chemotherapy of Breast Cancer","status":"UNKNOWN","sponsor":"Auxilio Mutuo Cancer Center","startDate":"2008-07","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT01093235","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2009-04","conditions":"Breast Cancer, Cardiac Toxicity, Perioperative/Postoperative Complications","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"epirubicin - cyclophosphamide / docetaxel + bevacizumab","genericName":"epirubicin - cyclophosphamide / docetaxel + bevacizumab","companyName":"GBG Forschungs GmbH","companyId":"gbg-forschungs-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Docetaxel is a taxane that stabilizes microtubules, preventing cell division. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), reducing angiogenesis. Used for Metastatic breast cancer, Locally advanced or metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}